Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Against the trial’s posted results

• Read here as one end of the posted intervalThis paper difference −27.0Posted, primary outcome difference −32.5 (−38.1 to −27.0), p <0.0001Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) AnalysisThe number read from the abstract is an end of the interval, not the estimate, so it does not vote.